RU2502736C2 - МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa - Google Patents

МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa Download PDF

Info

Publication number
RU2502736C2
RU2502736C2 RU2010154089/04A RU2010154089A RU2502736C2 RU 2502736 C2 RU2502736 C2 RU 2502736C2 RU 2010154089/04 A RU2010154089/04 A RU 2010154089/04A RU 2010154089 A RU2010154089 A RU 2010154089A RU 2502736 C2 RU2502736 C2 RU 2502736C2
Authority
RU
Russia
Prior art keywords
ureido
alkylene
oxo
dioxa
trien
Prior art date
Application number
RU2010154089/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010154089A (ru
Inventor
Кристофер КАЛЛУС
Марк БРЕНСТРУП
Андреас ЭФЕРС
Аня ГЛОБИШ
Херман ШРОЙДЕР
Михель ВАГНЕР
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of RU2010154089A publication Critical patent/RU2010154089A/ru
Application granted granted Critical
Publication of RU2502736C2 publication Critical patent/RU2502736C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2010154089/04A 2008-06-06 2009-05-22 МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa RU2502736C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290520.9 2008-06-06
EP08290520 2008-06-06
PCT/EP2009/003650 WO2009146802A1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (2)

Publication Number Publication Date
RU2010154089A RU2010154089A (ru) 2012-07-20
RU2502736C2 true RU2502736C2 (ru) 2013-12-27

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010154089/04A RU2502736C2 (ru) 2008-06-06 2009-05-22 МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa

Country Status (34)

Country Link
US (5) US8580777B2 (enExample)
EP (1) EP2300462B1 (enExample)
JP (1) JP5531011B2 (enExample)
KR (1) KR101673886B1 (enExample)
CN (1) CN102056922B (enExample)
AR (1) AR072007A1 (enExample)
AU (1) AU2009254257B2 (enExample)
BR (1) BRPI0913349A2 (enExample)
CA (1) CA2726554C (enExample)
CL (1) CL2009001358A1 (enExample)
CO (1) CO6321271A2 (enExample)
CR (1) CR11807A (enExample)
CY (1) CY1115604T1 (enExample)
DK (1) DK2300462T3 (enExample)
DO (1) DOP2010000363A (enExample)
EC (1) ECSP10010655A (enExample)
ES (1) ES2494390T3 (enExample)
HN (1) HN2010002558A (enExample)
HR (1) HRP20140787T1 (enExample)
IL (1) IL209772A (enExample)
MA (1) MA32322B1 (enExample)
MX (1) MX2010012793A (enExample)
NI (1) NI201000203A (enExample)
NZ (1) NZ589671A (enExample)
PL (1) PL2300462T3 (enExample)
PT (1) PT2300462E (enExample)
RU (1) RU2502736C2 (enExample)
SI (1) SI2300462T1 (enExample)
SV (1) SV2010003747A (enExample)
TW (1) TWI455928B (enExample)
UA (1) UA104002C2 (enExample)
UY (1) UY31868A (enExample)
WO (1) WO2009146802A1 (enExample)
ZA (1) ZA201007719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2300462T3 (da) 2008-06-06 2014-08-18 Sanofi Sa Makrocykliske carbamid- og sulfamidderivater som inhibitorer af tafia
EP2321301A4 (en) 2008-06-23 2011-09-28 Astrazeneca Ab NOVEL HETEROCYCLIC CARBOXAMIDES AS THROMBIN INHIBITORS
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
AP2014007881A0 (en) * 2012-03-06 2014-08-31 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2014198620A1 (en) * 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064686A1 (en) * 2000-02-29 2001-09-07 Universita' Degli Studi Di Firenze 3-aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries
RU2246498C2 (ru) * 1998-04-03 2005-02-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ацилбензоксазины для усиления синаптического ответа (ов)
WO2005105781A1 (de) * 2004-04-22 2005-11-10 Sanofi-Aventis Deutschland Gmbh Imidazol-derivate als tafia-inhibitoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
JP2001514245A (ja) 1997-08-28 2001-09-11 ファルマシア・アンド・アップジョン・カンパニー タンパク質チロシンホスファターゼ阻害剤
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
AU2007327959B2 (en) 2006-12-06 2013-08-01 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
DK2300462T3 (da) 2008-06-06 2014-08-18 Sanofi Sa Makrocykliske carbamid- og sulfamidderivater som inhibitorer af tafia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2246498C2 (ru) * 1998-04-03 2005-02-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ацилбензоксазины для усиления синаптического ответа (ов)
WO2001064686A1 (en) * 2000-02-29 2001-09-07 Universita' Degli Studi Di Firenze 3-aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries
WO2005105781A1 (de) * 2004-04-22 2005-11-10 Sanofi-Aventis Deutschland Gmbh Imidazol-derivate als tafia-inhibitoren

Also Published As

Publication number Publication date
US9309207B2 (en) 2016-04-12
RU2010154089A (ru) 2012-07-20
US20110178130A1 (en) 2011-07-21
MA32322B1 (fr) 2011-05-02
TW201008917A (en) 2010-03-01
MX2010012793A (es) 2010-12-14
ECSP10010655A (es) 2011-01-31
CN102056922A (zh) 2011-05-11
HN2010002558A (es) 2012-08-28
ES2494390T3 (es) 2014-09-15
TWI455928B (zh) 2014-10-11
CO6321271A2 (es) 2011-09-20
US20160024033A1 (en) 2016-01-28
CN102056922B (zh) 2013-11-20
DK2300462T3 (da) 2014-08-18
HRP20140787T1 (hr) 2014-11-21
AU2009254257B2 (en) 2013-11-21
US8580777B2 (en) 2013-11-12
KR101673886B1 (ko) 2016-11-08
JP2011521981A (ja) 2011-07-28
PT2300462E (pt) 2014-08-05
EP2300462A1 (de) 2011-03-30
AR072007A1 (es) 2010-07-28
HK1152936A1 (en) 2012-03-16
US9688645B2 (en) 2017-06-27
BRPI0913349A2 (pt) 2015-11-24
CA2726554C (en) 2015-02-24
UA104002C2 (ru) 2013-12-25
US20140039011A1 (en) 2014-02-06
KR20110020795A (ko) 2011-03-03
NI201000203A (es) 2011-09-29
DOP2010000363A (es) 2010-12-15
CA2726554A1 (en) 2009-12-10
US9126955B2 (en) 2015-09-08
IL209772A (en) 2016-04-21
CY1115604T1 (el) 2017-01-04
AU2009254257A1 (en) 2009-12-10
US20160251324A1 (en) 2016-09-01
SV2010003747A (es) 2011-03-15
US20140206760A1 (en) 2014-07-24
PL2300462T3 (pl) 2014-10-31
UY31868A (es) 2010-01-05
NZ589671A (en) 2012-03-30
SI2300462T1 (sl) 2014-09-30
CR11807A (es) 2011-02-16
US8722655B2 (en) 2014-05-13
EP2300462B1 (de) 2014-05-21
JP5531011B2 (ja) 2014-06-25
WO2009146802A1 (de) 2009-12-10
CL2009001358A1 (es) 2009-11-27
ZA201007719B (en) 2011-07-27
IL209772A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
RU2502736C2 (ru) МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
RU2446157C2 (ru) Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa
AU2007327959B2 (en) Urea and sulfamide derivatives as tafia inhibitors
RU2446160C2 (ru) Тартратные производные для применения в качестве ингибиторов фактора свертывания крови ixa
JP2008504315A (ja) Mmp阻害剤の形態で使用される置換テトラヒドロイソキノリン、その製造法および薬剤としての使用
US7863269B2 (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
HK1152936B (en) Macrocyclic urea derivatives and sulfamide derivatives as inhibitors of tafia

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180523